Pumping Iron: IV Supplement Helps Heart Failure Patients

"The trial demonstrates, in more than 1,100 patients, that intravenous ferric carboxymaltose treatment in iron deficient patients hospitalized with heart failure reduces subsequent hospitalizations without an impact on mortality," Dr. Nancy K. Sweitzer said.

Also read, "Intravenous Iron Reduces HF Readmissions: AFFIRM-AHF," Medscape, Nov. 14, 2020 - "Patients with iron deficiency tend to be elderly with more comorbidities, have longer hospital lengths of stay, and higher readmission rates. "So impacting hospitalizations in this population is incredibly impactful," she said."